A Randomised, Double-Blind, Multinational, Multicenter, Placebo-controlled Parallel Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg o.d. and 150 mg o.d.) Given During 12 weeks in Comparison with Placebo in the Treatment of Subjects with Lamellar Ichthyosis

• Conditions: amellar Ichtyosis; MedDRA version: 6.1Level: HLTClassification code 10021197

• Registration Number: EUCTR2005-000842-35-IT
• Lead Sponsor: BARRIER THERAPEUTICS, INC.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10-26
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified